Phaseline

Targets › LSD1

LSD1 (Lysine-specific histone demethylase 1A): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2028.

Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. (UniProt, O60341)

Open in Phaseline: the race on LSD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jubilant TherapeuticsJBI-802
CoREST inhibitor dual targeting LSD1 and HDAC6
LSD1, HDAC (class I/II)Phase 1Essential Thrombocythemia (ET); Lung Cancer (NSCLC)Jun 2028

Conditions

Essential Thrombocythemia (ET) (1) Lung Cancer (NSCLC) (1)

Modalities

small molecule (1)

Companies

Jubilant Therapeutics (1)

Related targets

HDAC (class I/II) (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.